In recent years, epigenetic clocks based on DNA methylation have evolved from research tools to widely used biomarkers of biological ageing. They correlate not only with chronological age, but also – depending on the “clock generation” – with morbidity, functional outcomes and mortality risks. At the same time, the step into clinical routine is challenging: measurement accuracy, comparability between tests, population generalizability and clinical decision limits have so far only been partially standardized.
Publikation
- Longevity-Special
You May Also Like
- Development of a quintuple agonist
New strategy in the fight against obesity and T2D
- From symptom to diagnosis
Oncocytoma
- Arterial elasticity, vascular ageing, endothelial function
Longevity and cardiovascular health 2025
- AI-supported risk stratification for chest pain in the emergency room
Performance of a fully automated ECG model
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Hormone balance and longevity
Ageing is not a substitution diagnosis
- Cardiovascular risk
Bad news for young men with T2D
- Case Report